Now that the FDA has forced GlaxoSmithKline (GSK) to put a "black label" on its diabetes drug Avandia, the competition is going for a coup de grace.
Takeda Pharmaceutical Co Ltd said on Thursday it was planning a major U.S. advertising campaign for diabetes drug Actos — one day after a new safety warning was issued on rival product Avandia, according to Reuters. The news service adds "the ads will run in 82 local newspapers and in several news weeklies, starting on Friday, under the headline "Actos has been shown to lower blood sugar without increasing your risk of having a heart attack or stroke.".
Never let it be said that the drug company executives are nice people.
Douglas A. McIntyre
Are You Ahead, or Behind on Retirement? (sponsor)
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.